Angioimmunoblastic T-Cell Lymphoma (AILT)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Angioimmunoblastic T-Cell Lymphoma

MalaCards integrated aliases for Angioimmunoblastic T-Cell Lymphoma:

Name: Angioimmunoblastic T-Cell Lymphoma 12 53 59 55 15 17 33
Immunoblastic Lymphadenopathy 53 59 44 17
T-Cell Lymphoma, Aild Type 53 59
Lymphogranulomatosis X 53 59
Angioimmunoblastic Lymphadenopathy 72
Aitl 53
Ailt 59


Orphanet epidemiological data:

angioimmunoblastic t-cell lymphoma
Age of onset: Adult;


External Ids:

Disease Ontology 12 DOID:0111147
MeSH 44 D007119
NCIt 50 C7528
SNOMED-CT 68 835009
ICD10 33 C86.5
ICD10 via Orphanet 34 C86.5
UMLS via Orphanet 73 C0020981
Orphanet 59 ORPHA86886
UMLS 72 C0020981

Summaries for Angioimmunoblastic T-Cell Lymphoma

Disease Ontology : 12 A peripheral T-cell lymphoma characterized by autoimmune features and poor prognosis.

MalaCards based summary : Angioimmunoblastic T-Cell Lymphoma, also known as immunoblastic lymphadenopathy, is related to lymphoma, hodgkin, classic and nodular lymphocyte predominant hodgkin lymphoma, and has symptoms including exanthema An important gene associated with Angioimmunoblastic T-Cell Lymphoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are Allograft rejection and ICos-ICosL Pathway in T-Helper Cell. The drugs Gemcitabine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Wikipedia : 75 Angioimmunoblastic T-cell lymphoma (AITL, sometimes misspelled AILT) (formerly known as... more...

Related Diseases for Angioimmunoblastic T-Cell Lymphoma

Diseases related to Angioimmunoblastic T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 246)
# Related Disease Score Top Affiliating Genes
1 lymphoma, hodgkin, classic 31.0 MME BCL6
2 nodular lymphocyte predominant hodgkin lymphoma 31.0 PDCD1 BCL6
3 marginal zone b-cell lymphoma 30.9 MME BCL6
4 panniculitis 30.7 TIA1 GZMB
5 composite lymphoma 30.5 TIA1 GZMB BCL6
6 peripheral t-cell lymphoma 30.5 TIA1 TET2 SYK MME ITK GZMB
7 hepatosplenic t-cell lymphoma 30.4 TIA1 GZMB
8 burkitt lymphoma 30.4 MME CXCL13 BCL6
9 lymphoma, non-hodgkin, familial 30.3 SYK MME GZMB BCL6
10 mantle cell lymphoma 30.0 SYK MME BCL6
11 spongiotic dermatitis 29.9 TBX21 PDCD1
12 myeloma, multiple 29.9 MME MAF IDH2
13 hematologic cancer 29.7 TET2 SYK MME BCL6
14 lymphoma 11.2
15 b-cell lymphoma 10.8
16 exanthem 10.8
17 diffuse large b-cell lymphoma 10.7
18 splenomegaly 10.7
19 polyclonal hypergammaglobulinemia 10.7
20 hemolytic anemia 10.7
21 lymphoproliferative syndrome 10.6
22 heart lymphoma 10.6 MME BCL6
23 thrombocytopenia 10.6
24 intravascular large b-cell lymphoma 10.6 MME BCL6
25 testicular lymphoma 10.5 MME BCL6
26 anemia, autoimmune hemolytic 10.5
27 t-cell/histiocyte rich large b cell lymphoma 10.5 MME BCL6
28 autoimmune disease 10.5
29 anaplastic large cell lymphoma 10.5
30 hypereosinophilic syndrome 10.5
31 folic acid deficiency anemia 10.5 TET2 MME
32 follicular lymphoma 10.5
33 purpura 10.5
34 central nervous system hematologic cancer 10.4 MME BCL6
35 acute salpingitis 10.4 MME CXCL13
36 pure red-cell aplasia 10.4
37 vasculitis 10.4
38 angioimmunoblastic lymphadenopathy with dysproteinemia 10.4
39 plasma cell leukemia 10.4
40 hematopoietic stem cell transplantation 10.4
41 red cell aplasia 10.4
42 autoimmune lymphoproliferative syndrome, type v 10.4 TIA1 BCL6
43 mycosis fungoides 10.4
44 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
45 adult t-cell leukemia 10.4
46 nephrotic syndrome 10.4
47 pancytopenia 10.4
48 glomerulonephritis 10.4
49 t-cell leukemia 10.4
50 leukemia, t-cell, chronic 10.4

Graphical network of the top 20 diseases related to Angioimmunoblastic T-Cell Lymphoma:

Diseases related to Angioimmunoblastic T-Cell Lymphoma

Symptoms & Phenotypes for Angioimmunoblastic T-Cell Lymphoma

UMLS symptoms related to Angioimmunoblastic T-Cell Lymphoma:


MGI Mouse Phenotypes related to Angioimmunoblastic T-Cell Lymphoma:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.81 BCL6 CXCL13 ICOS ITK PDCD1 SYK
2 endocrine/exocrine gland MP:0005379 9.8 BCL6 ICOS ITK PDCD1 SYK TBX21
3 immune system MP:0005387 9.7 BCL6 CXCL13 ICOS ITK MAF MME
4 neoplasm MP:0002006 9.02 ICOS IDH2 PDCD1 TBX21 TET2

Drugs & Therapeutics for Angioimmunoblastic T-Cell Lymphoma

Drugs for Angioimmunoblastic T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 318)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Gemcitabine Approved Phase 4 95058-81-4 60750
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
Ifosfamide Approved Phase 4 3778-73-2 3690
leucovorin Approved Phase 4 58-05-9 143 6006
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Pirarubicin Investigational Phase 4 72496-41-4
12 HIV Protease Inhibitors Phase 4
protease inhibitors Phase 4
14 BB 1101 Phase 4
asparaginase Phase 4
16 Anti-Inflammatory Agents Phase 4
17 glucocorticoids Phase 4
18 Antineoplastic Agents, Hormonal Phase 4
19 Hormone Antagonists Phase 4
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
21 Dermatologic Agents Phase 4
Isophosphamide mustard Phase 4 0
23 Folic Acid Antagonists Phase 4
24 Folate Phase 4
25 Vitamin B Complex Phase 4
26 Vitamin B9 Phase 4
27 Nucleic Acid Synthesis Inhibitors Phase 4
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
31 Orange Approved Phase 3
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
Ondansetron Approved Phase 3 99614-02-5 4595
Morphine Approved, Investigational Phase 3 57-27-2 5288826
Dalteparin Approved Phase 3 9005-49-6
Ofloxacin Approved Phase 3 82419-36-1 4583
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
Romidepsin Approved, Investigational Phase 3 128517-07-7 5352062
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
49 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
50 Cytochrome P-450 Enzyme Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 263)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs) Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
2 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
3 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
4 Phase III Study of CHOP-14 Plus or Minus Alemtuzumab in Peripheral T-cell Lymphoma of the Elderly Unknown status NCT00725231 Phase 3 chemotherapy
5 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
6 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
7 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
8 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
9 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
10 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
11 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
12 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
13 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
14 A Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior To Autologous Stem Cell Transplant And Followed By Maintenance Rituximab Versus Observation Completed NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
15 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
16 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
17 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
18 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
19 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
20 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
21 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
22 Randomized Phase 3 Study Evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patient With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma Recruiting NCT03593018 Phase 3 Oral azacitidine;Romidepsin;Bendamustine;Gemcitabine
23 Randomized Phase 3 Study Evaluation the Efficacy and Safety of Oral Azacitidine(CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma Recruiting NCT03703375 Phase 3 Azacitidine;Romidepsin;Gemcitabine
24 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
25 CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Not yet recruiting NCT04021082 Phase 2, Phase 3 Cerdulatinib
26 Phase II Trial of Fludarabine & Cyclophosphamide Followed by Thalidomide for Angioimmunoblastic Lymphoma Unknown status NCT00958854 Phase 2 cyclophosphamide;fludarabine phosphate;thalidomide
27 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
28 Allograft of Hematopoietic Stem Cells With Reduced-intensity Conditioning From a HLA-haploidentical Family Donor: Phase II Study of Combined Immunosuppression Before and After Transplantation Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
29 Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
30 Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
31 Phase 2 Study of Endostar Combined With CHOP Regimen as the First Line Chemotherapy for Untreated Peripheral T Cell Lymphoma Unknown status NCT00974324 Phase 2 endostar and CHOP
32 A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
33 A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study of AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, That Harbor an IDH2 Mutation Completed NCT02273739 Phase 1, Phase 2 AG-221
34 A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2 oxaliplatin
35 A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;Vincristine;pralatrexate
36 A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma: BENCART Trial Completed NCT02424045 Phase 2 BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)
37 Phase II Study of Arsenic Trioxide (NSC #706363) in Relapsed and Refractory Intermediate and High-Grade Non-Hodgkin's Lymphoma Completed NCT00005040 Phase 2 arsenic trioxide
38 A Phase 1/2a Open-label Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Lymphoproliferative Malignancies Completed NCT00481871 Phase 1, Phase 2 Pralatrexate Injection;Gemcitabine Hydrochloride
39 Gem-CHOP: A Randomized Phase II Study of Gemcitabine Combined With CHOP in Untreated Aggressive Non-Hodgkin's Lymphoma Completed NCT00079261 Phase 2 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;gemcitabine hydrochloride;prednisone;vincristine sulfate
40 Diffuse Large B Cell And Peripheral T-Cell Non-Hodgkin's Lymphoma In The Frail Elderly. Progressive And Cautious Treatment Strategy In Poor Status Patients. A Phase II Trial With Emphasis On Geriatric Assessment And Quality Of Life Completed NCT00039351 Phase 2 cyclophosphamide;prednisone;vincristine sulfate
41 An Open-Label, Intravenous To Oral Switch, Multiple Dose, Multi-Center Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Hospitalized Children Aged 2 - <12 Years Who Require Treatment For The Prevention Of Systemic Fungal Infection Completed NCT00066599 Phase 2 voriconazole
43 Study of the Efficacy and the Safety of First Line Treatment With CHOP Plus Rituximab (R-CHOP) in Patients Aged 60 to 80 Years With Previously Untreated T-cell Angioimmunoblastic Lymphoma (AIL). Completed NCT00169156 Phase 2 Rituximab;Prednisone;Doxorubicine;Cyclophosphamide;Vincristine
44 A Phase II Study of 506U78 in Patients With Previously Systemically Untreated Cutaneous T-cell Lymphoma (CTCL) or With Refractory or Relapsed Non-cutaneous Peripheral T-cell Lymphoma (PTCL) Completed NCT00005080 Phase 2 nelarabine
45 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
46 Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy Completed NCT00255749 Phase 2
47 Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
48 Ex Vivo Expanded Megakaryocytes for Supportive Care of Breast Cancer Patients: A Phase I/II Study Completed NCT00006225 Phase 1, Phase 2
49 Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen Completed NCT00005804 Phase 2 cyclophosphamide
50 A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide

Search NIH Clinical Center for Angioimmunoblastic T-Cell Lymphoma

Cochrane evidence based reviews: immunoblastic lymphadenopathy

Genetic Tests for Angioimmunoblastic T-Cell Lymphoma

Anatomical Context for Angioimmunoblastic T-Cell Lymphoma

MalaCards organs/tissues related to Angioimmunoblastic T-Cell Lymphoma:

T Cells, B Cells, Bone, Bone Marrow, Lymph Node, Nk Cells, Endothelial

Publications for Angioimmunoblastic T-Cell Lymphoma

Articles related to Angioimmunoblastic T-Cell Lymphoma:

(show top 50) (show all 1099)
# Title Authors PMID Year
Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma. 9 38
18792075 2008
Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. 9 38
16680156 2006
Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. 9 38
16625095 2006
CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry. 9 38
16084948 2005
Molecular-cytogenetic characterization of non-Hodgkin's lymphoma with double and cryptic translocations of the immunoglobulin heavy chain gene. 9 38
15370207 2004
Cutaneous lesions of angioimmunoblastic T-cell lymphoma: Clinical, pathological, and immunophenotypic features. 38
30980412 2019
Application of a 5 Marker Panel to the Routine Diagnosis of Peripheral T-Cell Lymphoma With T-Follicular Helper Phenotype. 38
31283630 2019
Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma. 38
31423206 2019
Cyclosporine for angioimmunoblastic T-cell lymphoma: a literature review. 38
31393197 2019
RHOA G17V mutation in angioimmunoblastic T-cell lymphoma: A potential biomarker for cytological assessment. 38
31394087 2019
The pathological features of angioimmunoblastic T-cell lymphomas with IDH2R172 mutations. 38
30952970 2019
A Survey of Somatic Mutations in 41 Genes in a Cohort of T-Cell Lymphomas Identifies Frequent Mutations in Genes Involved in Epigenetic Modification. 38
29629950 2019
Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma. 38
30985955 2019
Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases. 38
30952973 2019
High-Throughput Sequence Analysis of Peripheral T-Cell Lymphomas Indicates Subtype-Specific Viral Gene Expression Patterns and Immune Cell Microenvironments. 38
31292228 2019
3D analysis of morphological alterations of the fibroblastic reticular cells in reactive and neoplastic human lymph nodes. 38
31285059 2019
Guillain Barré syndrome heralding the diagnosis of angioimmunoblastic T-cell lymphoma. 38
30648445 2019
Successful treatment with mogamulizumab of refractory/relapsed angioimmunoblastic T-cell lymphoma following autologous stem cell transplantation. 38
30732495 2019
Monoclonal plasma cell infiltrates in the setting of cutaneous follicular helper T cell lymphoproliferative disorders. 38
31077877 2019
Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1 - azacitidine induces only lymphoma remission. 38
31204875 2019
Differentiation of angioimmunoblastic T-cell lymphoma from DRESS syndrome. 38
30557716 2019
FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma. 38
30914464 2019
The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. 38
30694529 2019
Deregulated expression of NKL homeobox genes in T-cell lymphomas. 38
31143370 2019
Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. 38
30782609 2019
A case of AITL complicated by EBV-positive B cell and monoclonal plasma cell proliferation and effectively treated with lenalidomide. 38
30604313 2019
Angioimmunoblastic T-cell lymphoma mimicking eosinophilic granulomatosis with polyangiitis (Churg-Strauss). 38
29966769 2019
Rare diseases that mimic Systemic Lupus Erythematosus (Lupus mimickers). 38
30837156 2019
[Interpretation of angioimmunoblastic T-cell lymphoma]. 38
30831661 2019
Unravelling Subtleties of Angioimmunoblastic T-Cell Lymphoma. 38
30861363 2019
Practical Treatment Approach for Angioimmunoblastic T-Cell Lymphoma. 38
30861367 2019
New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination. 38
30782038 2019
Metronidazole-induced encephalopathy during treatment for refractory diarrhea after cord blood transplantation. 38
30835083 2019
Moving Toward Targeted Therapy in the Treatment of Angioimmunoblastic T-Cell Lymphoma. 38
30861369 2019
Effectiveness of cord blood transplantation for the treatment of refractory angioimmunoblastic T-cell lymphoma: a series of three cases. 38
30809041 2019
Bexarotene in Patients With Peripheral T-cell Lymphomas: Results of a Retrospective Study. 38
30448048 2019
Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma. 38
30430419 2019
EBV-Related Diffuse Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma 38
30066674 2019
Chylous ascites, anti-interferon-gamma autoantibody, and angioimmunoblastic T-cell lymphoma: a rare but intriguing connection over Mycobacterium avium. 38
30083859 2019
Cutaneous localization of angioimmunoblastic T-cell lymphoma may masquerade as B-cell lymphoma or classical Hodgkin lymphoma: A histologic diagnostic pitfall. 38
30370547 2019
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. 38
30332497 2019
Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma. 38
30596212 2019
Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. 38
30630534 2019
Identification of hub genes and key pathways associated with angioimmunoblastic T-cell lymphoma using weighted gene co-expression network analysis. 38
31239775 2019
Extreme Peripheral Blood Plasmacytosis Mimicking Plasma Cell Leukemia as a Presenting Feature of Angioimmunoblastic T-Cell Lymphoma (AITL). 38
31263679 2019
Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma. 38
30327172 2019
Candidate susceptibility variants in angioimmunoblastic T-cell lymphoma. 38
30097855 2019
Angioimmunoblastic T-Cell Lymphoma. 38
30596215 2019
ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma. 38
30814910 2019
Interleukin-17-producing angioimmunoblastic T-cell lymphoma with Evans syndrome. 38
30592297 2019

Variations for Angioimmunoblastic T-Cell Lymphoma

Cosmic variations for Angioimmunoblastic T-Cell Lymphoma:

# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM78415 RHOA haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,peripheral T cell lymphoma unspecified c.50G>T p.G17V 3:49375540-49375540 0

Expression for Angioimmunoblastic T-Cell Lymphoma

Search GEO for disease gene expression data for Angioimmunoblastic T-Cell Lymphoma.

Pathways for Angioimmunoblastic T-Cell Lymphoma

GO Terms for Angioimmunoblastic T-Cell Lymphoma

Biological processes related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine production GO:0001816 8.96 MAF ITK
2 germinal center formation GO:0002467 8.62 CXCL13 BCL6

Molecular functions related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 non-membrane spanning protein tyrosine kinase activity GO:0004715 8.62 SYK ITK

Sources for Angioimmunoblastic T-Cell Lymphoma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....